122833-23-2

Basic information

• Product Name: 3,3-ethylenedioxy-5α-hydroxy-11β-[4-(thiomethoxy)phenyl]-estr-9-en-17-one
• Synonyms: 3,3-ethylenedioxy-5α-hydroxy-11β-[4-(thiomethoxy)phenyl]-estr-9-en-17-one
• CAS NO: 122833-23-2
• Molecular Weight: 454.631
• Mol File: 122833-23-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3,3-ethylenedioxy-5α-hydroxy-11β-[4-(thiomethoxy)phenyl]-estr-9-en-17-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-ethylenedioxy-5α-hydroxy-11β-[4-(thiomethoxy)phenyl]-estr-9-en-17-one(122833-23-2)
• EPA Substance Registry System: 3,3-ethylenedioxy-5α-hydroxy-11β-[4-(thiomethoxy)phenyl]-estr-9-en-17-one(122833-23-2)

Safety Data

• Hazardous Substances Data: 122833-23-2(Hazardous Substances Data)

Upstream product

• 18620-04-7 4-thioanisolemagnesium bromide 
• 39931-88-9 (5'R,10'R,13'S)-13'-methyl-1',2',6',7',8',12',13',14',15',16'-decahydro-17'H-spiro[1,3-dioxolane-2,3'-[5,10]epoxycyclopenta[a]phenanthren]-17'-one 
• 5571-36-8 ethylene deltenone 

Downstream Products

• 947394-74-3 3,3-ethylenedioxy-5α,17β-dihydroxy-11β-[4-(thiomethoxy)phenyl]-19-nor-17α-pregn-9-ene-21-ethyne 

Relevant articles and documents

LIF/LIFR ANTAGONIST IN ONCOLOGY AND NONMALIGNANT DISEASES

Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and/or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.

17-PHOSPHOROUS STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS

The present invention is directed to novel 17-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.

Novel phosphorus-containing 17β-side chain mifepristone analogues as progesterone receptor antagonists

A novel series of steroidal compounds were designed and synthesized with various phosphorus-containing groups on the 17β-side chain as progesterone receptor antagonists. The structure-activity relationships of these compounds are discussed. Selected compo